Abstract 361P
Background
Thoracic stereotactic body radiotherapy (SBRT) is widely applied in both early and metastatic disease. Pathological CR rate after SBRT was quoted around 60%. Thus, it is important to predict responder and non-responder to SBRT. With advent of radiomics, textual features of tumor can be extracted from imaging. We propose a model to predict radiological response after SBRT based on tumor radiomics features regardless of histology and staging.
Methods
Patients receiving thoracic SBRT using active breathing control (ABC) were retrospectively recruited regardless of tumor histology/primary and staging. All patients received 50-54 Gy in 3-4 fractions equivalent to BED >100Gy. All patients had regular contrast CT Thorax per protocol and PET/CT if indicated. Tumor response was assessed by an independent senior radiologist based on RECIST criteria. Responders are defined as complete response (CR) or partial response (PR). Non-responders were defined as those with stable or progressive disease. Gross tumor volumes (GTV) were contoured on the initial planning CT. 110 radiomics features including voxel intensities, textual and gray level features were extracted using pyradiomics module. The features were then analyzed using in-house software. A model using support vector machine (SVM) was trained to predict response based solely on the extracted radiomics features. 10-fold cross validation was used to avoid overfitting. ROC curves were constructed to evaluate model performance.
Results
68 patients were recruited from 2008 to 2018. 54 patients had lung primaries while 14 patients had thoracic oligo-metastases. Secondaries include colorectal, head and neck squamous cell carcinoma and hepatocellular carcinoma. 85 tumors were analyzed, of which 31 tumors had CR and 11 tumors had PR. The radiomic model developed had an accuracy of 74.8%. The AUC for CR, PR and non-responder prediction was 0.865 (95% CI: 0.794 – 0.921), 0.946 (95% CI: 0.873 – 0.978) and 0.857 (95% CI: 0.789 – 0.915) respectively. Under the threshold, the sensitivity was 89% while the specificity was 68% for detecting non-responders.
Conclusions
Radiomic is a promising technique that can predict tumor response with good accuracy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Clinical Oncology, Queen Mary Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session